iTeos Therapeutics (ITOS) Competitors $7.46 -0.01 (-0.07%) As of 10:04 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ITOS vs. IOVA, WVE, ETNB, COLL, MLYS, NTLA, SYRE, ZYME, RCUS, and NRIXShould you be buying iTeos Therapeutics stock or one of its competitors? The main competitors of iTeos Therapeutics include Iovance Biotherapeutics (IOVA), Wave Life Sciences (WVE), 89bio (ETNB), Collegium Pharmaceutical (COLL), Mineralys Therapeutics (MLYS), Intellia Therapeutics (NTLA), Spyre Therapeutics (SYRE), Zymeworks (ZYME), Arcus Biosciences (RCUS), and Nurix Therapeutics (NRIX). These companies are all part of the "pharmaceutical products" industry. iTeos Therapeutics vs. Iovance Biotherapeutics Wave Life Sciences 89bio Collegium Pharmaceutical Mineralys Therapeutics Intellia Therapeutics Spyre Therapeutics Zymeworks Arcus Biosciences Nurix Therapeutics iTeos Therapeutics (NASDAQ:ITOS) and Iovance Biotherapeutics (NASDAQ:IOVA) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, institutional ownership, community ranking, dividends, risk, profitability, analyst recommendations, valuation and media sentiment. Do analysts prefer ITOS or IOVA? iTeos Therapeutics currently has a consensus price target of $25.75, indicating a potential upside of 245.17%. Iovance Biotherapeutics has a consensus price target of $18.22, indicating a potential upside of 442.33%. Given Iovance Biotherapeutics' higher possible upside, analysts clearly believe Iovance Biotherapeutics is more favorable than iTeos Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score iTeos Therapeutics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00Iovance Biotherapeutics 0 Sell rating(s) 1 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.89 Does the MarketBeat Community favor ITOS or IOVA? Iovance Biotherapeutics received 526 more outperform votes than iTeos Therapeutics when rated by MarketBeat users. However, 80.70% of users gave iTeos Therapeutics an outperform vote while only 74.48% of users gave Iovance Biotherapeutics an outperform vote. CompanyUnderperformOutperformiTeos TherapeuticsOutperform Votes4680.70% Underperform Votes1119.30%Iovance BiotherapeuticsOutperform Votes57274.48% Underperform Votes19625.52% Do insiders & institutionals have more ownership in ITOS or IOVA? 97.2% of iTeos Therapeutics shares are owned by institutional investors. Comparatively, 77.0% of Iovance Biotherapeutics shares are owned by institutional investors. 12.5% of iTeos Therapeutics shares are owned by company insiders. Comparatively, 12.1% of Iovance Biotherapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Which has higher earnings & valuation, ITOS or IOVA? iTeos Therapeutics has higher earnings, but lower revenue than Iovance Biotherapeutics. Iovance Biotherapeutics is trading at a lower price-to-earnings ratio than iTeos Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioiTeos Therapeutics$35M8.14-$112.64M-$3.31-2.25Iovance Biotherapeutics$164.07M6.71-$444.04M-$1.30-2.58 Which has more volatility and risk, ITOS or IOVA? iTeos Therapeutics has a beta of 1.43, suggesting that its share price is 43% more volatile than the S&P 500. Comparatively, Iovance Biotherapeutics has a beta of 1.05, suggesting that its share price is 5% more volatile than the S&P 500. Does the media refer more to ITOS or IOVA? In the previous week, Iovance Biotherapeutics had 9 more articles in the media than iTeos Therapeutics. MarketBeat recorded 13 mentions for Iovance Biotherapeutics and 4 mentions for iTeos Therapeutics. iTeos Therapeutics' average media sentiment score of 1.21 beat Iovance Biotherapeutics' score of 0.82 indicating that iTeos Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment iTeos Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Iovance Biotherapeutics 6 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Is ITOS or IOVA more profitable? iTeos Therapeutics has a net margin of 0.00% compared to Iovance Biotherapeutics' net margin of -451.25%. iTeos Therapeutics' return on equity of -20.11% beat Iovance Biotherapeutics' return on equity.Company Net Margins Return on Equity Return on Assets iTeos TherapeuticsN/A -20.11% -17.50% Iovance Biotherapeutics -451.25%-58.43%-45.48% SummaryiTeos Therapeutics beats Iovance Biotherapeutics on 11 of the 18 factors compared between the two stocks. Get iTeos Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ITOS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ITOS vs. The Competition Export to ExcelMetriciTeos TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$284.93M$2.93B$5.40B$7.70BDividend YieldN/A1.91%5.44%4.32%P/E Ratio-2.3730.4322.2418.31Price / Sales8.14478.74402.05107.05Price / CashN/A168.6838.2034.62Price / Book0.463.786.844.25Net Income-$112.64M-$72.06M$3.20B$247.51M7 Day Performance14.59%11.17%5.91%6.33%1 Month Performance14.59%-4.87%-4.20%-3.33%1 Year Performance-29.62%-18.74%18.03%5.15% iTeos Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ITOSiTeos Therapeutics2.2831 of 5 stars$7.46-0.1%$25.75+245.4%-29.4%$283.32M$35M-2.3590IOVAIovance Biotherapeutics4.2225 of 5 stars$3.08+0.7%$18.22+491.6%-71.3%$1.01B$164.07M-2.07500WVEWave Life Sciences4.3329 of 5 stars$6.12+3.4%$22.18+262.4%+35.5%$939.33M$108.30M-5.51240Positive NewsETNB89bio2.9722 of 5 stars$6.27+3.5%$27.56+339.5%-19.6%$915.32MN/A-2.1540Analyst ForecastOptions VolumeGap DownCOLLCollegium Pharmaceutical4.0114 of 5 stars$26.91-0.4%$43.60+62.0%-24.5%$864.67M$631.45M11.60210MLYSMineralys Therapeutics2.6183 of 5 stars$13.24-0.8%$33.00+149.2%+24.0%$858.96MN/A-3.6428Positive NewsNTLAIntellia Therapeutics4.5461 of 5 stars$7.92+9.5%$36.68+363.2%-61.4%$819.86M$57.88M-1.46600Analyst RevisionHigh Trading VolumeSYRESpyre Therapeutics1.8134 of 5 stars$13.57+7.1%$49.57+265.3%-54.7%$817.95M$890,000.00-1.82100Positive NewsGap DownZYMEZymeworks2.7324 of 5 stars$11.75+1.9%$21.00+78.7%+46.4%$817.53M$76.30M-7.83460Positive NewsRCUSArcus Biosciences2.1376 of 5 stars$7.68-2.5%$30.25+293.9%-45.5%$807.46M$258M-2.44500Analyst ForecastNRIXNurix Therapeutics2.3926 of 5 stars$10.55+3.0%$30.44+188.6%-16.2%$804.29M$56.42M-3.65300Positive News Related Companies and Tools Related Companies IOVA Competitors WVE Competitors ETNB Competitors COLL Competitors MLYS Competitors NTLA Competitors SYRE Competitors ZYME Competitors RCUS Competitors NRIX Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ITOS) was last updated on 4/25/2025 by MarketBeat.com Staff From Our PartnersElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | Sponsored[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredFeds Just Admitted It—They Can Take Your CashHere’s the cold truth: If your money is sitting idle in a bank account, it’s vulnerable. That’s why thousan...Priority Gold | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | Sponsored"I'm risking my reputation on this"I've discovered something so significant about the 2025 crypto market that I had to put everything else aside ...Crypto 101 Media | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding iTeos Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share iTeos Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
